Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-ALK CAR T cells

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting the human receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-ALK CAR T-cell recognize and induce selective toxicity against ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-ALK CAR-T cells
autologous hALK CAR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search